{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T20:29:58Z","timestamp":1790368198639,"version":"4.1.0"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,2,3]],"date-time":"2022-02-03T00:00:00Z","timestamp":1643846400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"abstract":"\n Background<\/jats:title>\n \n Pulmonary tuberculosis (PTB) often results in residual anatomical and functional changes despite microbiological cure and may be complicated by chronic pulmonary aspergillosis (CPA). In this study, we determined the perceived health-related quality of life (HRQoL) of patients during and after PTB therapy and compared it with their quantitative\n Aspergillus<\/jats:italic>\n -specific IgG positivity rates.\n <\/jats:p>\n <\/jats:sec>\n \n Methodology<\/jats:title>\n \n We conducted a longitudinal study among TB patients attending two directly observed therapy short-course (DOTS) clinics in Lagos, Nigeria. Two hundred and four confirmed TB patients were recruited over 9\u00a0months, with five visits at baseline and 3, 6, 9, and 12\u00a0months. They were all acid-fast bacilli smear, GeneXpert, or culture positive for\n Mycobacterium tuberculosis<\/jats:italic>\n . Two HRQoL questionnaires translated into Yoruba were self-administered. Chest X-ray and\n Aspergillus<\/jats:italic>\n IgG were collected at each visit.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n A total of 204 participants were recruited into this study. Most (70.6%) were age 18\u201339\u00a0years, and only 3.9% were above 60\u00a0years; 66.7% of all participants were males. A total of 189 (92.6%) participated in the 3-month assessment, 174 (85.3%) at 6\u00a0months, 139 (68.1%) at 9\u00a0months, and 99 (48.5%) at 12\u00a0months. At baseline, only 60.9% scored \u201cgood\u201d or \u201cvery good\u201d QoL and health on the WHOQOL-Bref, which improved to 77% at 6\u00a0months. At baseline, 10.4% had positive\n Aspergillus<\/jats:italic>\n IgG levels, 15.1% at 3\u00a0months, 11.5% at 6\u00a0months, 16.7% at 9\u00a0months, and 19.3% at 12\u00a0months. Those with a positive\n Aspergillus<\/jats:italic>\n IgG at 6\u00a0months had worse physical health (\n p<\/jats:italic>\n \u00a0=\u00a00.001), psychological state (\n p<\/jats:italic>\n \u00a0=\u00a00.002), social relationships (\n p<\/jats:italic>\n \u00a0=\u00a00.006), and environmental QoL (\n p<\/jats:italic>\n \u00a0=\u00a00.001) domains of the WHOQOL-Bref. Probable CPA was 10.4% at baseline and 19.3% at 6\u00a0months post-PTB therapy. Thirty-eight (18.6%) relocated after 6\u00a0months of treatment, 16 (7.8%) were lost to follow-up, and 11 (5.4%) died.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n \n Our findings reveal a significant relationship between the QoL and\n Aspergillus<\/jats:italic>\n IgG levels of TB patients. Further follow-up studies and additional imaging are required to determine when patients develop CPA and its clinical impact.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.3389\/fcimb.2022.790134","type":"journal-article","created":{"date-parts":[[2022,2,3]],"date-time":"2022-02-03T03:58:32Z","timestamp":1643860712000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Prospective Evaluation of Positivity Rates of Aspergillus-Specific IgG and Quality of Life in HIV-Negative Tuberculosis Patients in Lagos, Nigeria"],"prefix":"10.3389","volume":"12","author":[{"given":"Rita O.","family":"Oladele","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Titi","family":"Gbajabimiala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Irurhe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne M.","family":"Skevington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David W.","family":"Denning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,2,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"88","DOI":"10.4081\/jphia.2014.366","article-title":"Factors Influencing Quality of Life and Predictors of Low Quality of Life Scores in Patients on Treatment for Pulmonary Tuberculosis: A Cross Sectional Study","volume":"5","author":"Adeyeye","year":"2014","journal-title":"J. Public Health Afr."},{"key":"B2","doi-asserted-by":"publisher","first-page":"100121","DOI":"10.1016\/j.jctube.2019.100121","article-title":"Quality of Life With Tuberculosis","volume":"17","author":"Aggarwal","year":"2019","journal-title":"J. Clin. Tuberc. Other Mycobact. Dis."},{"key":"B3","doi-asserted-by":"publisher","first-page":"947","DOI":"10.5588\/ijtld.12.0299","article-title":"Assessment of Health-Related Quality of Life in Patients With Pulmonary Tuberculosis Under Programme Conditions","volume":"17","author":"Aggarwal","year":"2013","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-12-19","article-title":"Impact of Tuberculosis Treatment on Health-Related Quality of Life of Pulmonary Tuberculosis Patients: A Follow-Up Study","volume":"12","author":"Atif","year":"2014","journal-title":"Health Qual. Life Outcomes"},{"key":"B5","unstructured":"St. George\u2019s Respiratory Questionnaire (SGRQ)"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-8-93","article-title":"Feasibility, Reliability and Validity of Health-Related Quality of Life Questionnaire Among Adult Pulmonary Tuberculosis Patients in Urban Uganda: Cross-Sectional Study","volume":"8","author":"Babikako","year":"2010","journal-title":"Health Qual. Life Outcomes"},{"key":"B7","doi-asserted-by":"publisher","first-page":"71","DOI":"10.4103\/0019-5359.110911","article-title":"Study of Impact of Antitubercular Therapy on Quality of Life","volume":"66","author":"Balgude","year":"2012","journal-title":"Indian J. Med. Sci."},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0193732","article-title":"Twelve-Month Clinical Outcomes of 206 Patients With Chronic Pulmonary Aspergillosis","volume":"13","author":"Bongomin","year":"2018","journal-title":"PloS One"},{"key":"B9","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.ijid.2014.12.045","article-title":"Health Status and Quality of Life in Tuberculosis","volume":"32","author":"Brown","year":"2015","journal-title":"Int. J. Infect. Dis."},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3201\/eid2408.171312","article-title":"Case Definition of Chronic Pulmonary Aspergillosis in Resource-Constrained Settings","volume":"24","author":"Denning","year":"2018","journal-title":"Emerging Infect. Dis."},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-7-105","article-title":"Tuberculosis and HIV Co-Infection: Its Impact on Quality of Life","volume":"7","author":"Deribew","year":"2009","journal-title":"Health Qual. Life Outcomes"},{"key":"B12","doi-asserted-by":"publisher","first-page":"850","DOI":"10.5588\/ijtld.13.0838","article-title":"Prevalence of Aspergillus Sensitisation in Pulmonary Tuberculosis-Related Fibrocavitary Disease","volume":"18","author":"Dhooria","year":"2014","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"B13","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1177\/1010539509336242","article-title":"A Study of the Impact of Tuberculosis on the Quality of Life and the Effect After Treatment With DOTS","volume":"21","author":"Dhuria","year":"2009","journal-title":"Asia Pac. J. Public Health"},{"key":"B14","first-page":"1361","article-title":"Relationship Between Quality of Life and Characteristics of Patients Hospitalised With Tuberculosis","volume":"9","author":"Duyan","year":"2005","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"B15","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/1477-7525-7-14","article-title":"Measuring Health-Related Quality of Life in Tuberculosis: A Systematic Review","volume":"7","author":"Guo","year":"2009","journal-title":"Health Qual. Life Outcomes"},{"key":"B16","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1023\/B:QURE.0000021317.12945.f0","article-title":"Quality of Life in Tuberculosis: Patient and Provider Perspectives","volume":"13","author":"Hansel","year":"2004","journal-title":"Qual. Life Res."},{"key":"B17","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1001\/archpsyc.1995.03950130011002","article-title":"Functioning and Well-Being Outcomes of Patients With Depression Compared With Chronic General Medical Illnesses","volume":"52","author":"Hays","year":"1995","journal-title":"Arch. Gen. Psychiatry"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12955-016-0442-6","article-title":"Health-Related Quality of Life and Its Association With Medication Adherence in Active Pulmonary Tuberculosis\u2013a Systematic Review of Global Literature With Focus on South Africa","volume":"14","author":"Kastien-Hilka","year":"2016","journal-title":"Health Qual. Life Outcomes"},{"key":"B19","first-page":"296","article-title":"Health Status of UK Patients With Active Tuberculosis","volume":"14","author":"Kruijshaar","year":"2010","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12890-017-0500-9","article-title":"Elevated Aspergillus-Specific Antibody Levels Among HIV Infected Ugandans With Pulmonary Tuberculosis","volume":"17","author":"Kwizera","year":"2017","journal-title":"BMC Pulm. Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1016\/0277-9536(95)00129-U","article-title":"Perception and Social Consequences of Tuberculosis: A Focus Group Study of Tuberculosis Patients in Sialkot, Pakistan","volume":"41","author":"Liefooghe","year":"1995","journal-title":"Soc. Sci. Med."},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-10-77","article-title":"Quality of Life Among Tuberculosis (TB), TB Retreatment and\/or TB-HIV Co-Infected Primary Public Health Care Patients in Three Districts in South Africa","volume":"10","author":"Louw","year":"2012","journal-title":"Health Qual. Life Outcomes"},{"key":"B23","doi-asserted-by":"publisher","first-page":"102","DOI":"10.5001\/omj.2014.25","article-title":"Assessment of Health-Related Quality of Life Among Patients With Tuberculosis in Hamadan, Western Iran","volume":"29","author":"Mamani","year":"2014","journal-title":"Oman Med. J."},{"key":"B24","first-page":"887","article-title":"Evaluation of Post-Treatment Health-Related Quality of Life (HRQoL) Among Tuberculosis Patients","volume":"11","author":"Muniyandi","year":"2007","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"B25","doi-asserted-by":"publisher","first-page":"532","DOI":"10.3390\/jof7070532","article-title":"Chronic Pulmonary Aspergillosis Situation Among Post Tuberculosis Patients in Vietnam: An Observational Study","volume":"7","author":"Nguyen","year":"2021","journal-title":"J. Fungi"},{"key":"B26","doi-asserted-by":"publisher","first-page":"283","DOI":"10.4314\/mmj.v30i4.12","article-title":"Health-Related Quality of Life (HRQoL) Scores Vary With Treatment and may Identify Potential Defaulters During Treatment of Tuberculosis","volume":"30","author":"Olufemi","year":"2018","journal-title":"Malawi Med. J."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1378\/chest.07-0755","article-title":"Using the St. George Respiratory Questionnaire to Ascertain Health Quality in Persons With Treated Pulmonary Tuberculosis","volume":"132","author":"Pasipanodya","year":"2007","journal-title":"Chest"},{"key":"B28","first-page":"869","article-title":"Socio-Economic Impact of Tuberculosis on Patients and Family in India","volume":"3","author":"Rajeswari","year":"1999","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/bmjgh-2017-000609","article-title":"How Will the Sustainable Development Goals Deliver Changes in Wellbeing? A Systematic Review and Meta-Analysis to Investigate Whether WHOQOL-BREF Scores Respond to Change","volume":"3","author":"Skevington","year":"2018","journal-title":"Br. Med. J. Global Health"},{"key":"B30","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1023\/B:QURE.0000018486.91360.00","article-title":"The World Health Organisation's WHOQOL-BREF Quality of Life Assessment: Psychometric Properties and Results of the International Field Trial- A Report From the WHOQOL Group","volume":"13","author":"Skevington","year":"2004","journal-title":"Qual. Life Res."},{"key":"B31","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1017\/S0033291798006667","article-title":"Development of the WHOQOL-BREF Quality of Life Assessment","volume":"28","year":"1998","journal-title":"Psychol. Med."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1016\/S0140-6736(15)60570-0","article-title":"WHO's New End TB Strategy","volume":"385","author":"Uplekar","year":"2015","journal-title":"Lancet"},{"key":"B33","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1183\/13993003.00535-2015","article-title":"The Minimal Important Difference for the St George's Respiratory Questionnaire in Patients With Severe COPD","volume":"46","author":"Welling","year":"2015","journal-title":"Eur. Respir. J."},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.mimet.2020.106021","article-title":"Optimising the Cut-Off of the Bordier Aspergillus IgG ELISA for the Diagnosis of Chronic Pulmonary Aspergillosis","volume":"176","author":"Wilopo","year":"2020","journal-title":"J. Microbiol. Methods"},{"key":"B35","volume-title":"Global Tuberculosis Report 2020","year":"2020"}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2022.790134\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,3]],"date-time":"2022-02-03T03:58:38Z","timestamp":1643860718000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2022.790134\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,3]]},"references-count":35,"alternative-id":["10.3389\/fcimb.2022.790134"],"URL":"https:\/\/doi.org\/10.3389\/fcimb.2022.790134","relation":{},"ISSN":["2235-2988"],"issn-type":[{"value":"2235-2988","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,3]]},"article-number":"790134"}}